• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Amgen

Amgen

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure

    Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure

  2. Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis

    Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis

  3. InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action

    InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action

  4. Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative

    Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative

  5. Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

    Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

  6. Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell

    Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell

  7. Noted Manager Stays Off the Beaten Path With New Global Fund

    David Iben kept a low profile when he left Nuveen Tradewinds, but now the contrarian is back to running a new global all-cap strategy.

  8. Despite bullish backdrop, technical tests are -6-

    Despite bullish backdrop, technical tests are -6-

  9. Despite bullish backdrop, technical tests are -2-

    Despite bullish backdrop, technical tests are -2-

  10. Despite bullish backdrop, technical tests are in play

    Despite bullish backdrop, technical tests are in play

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.